Planning Rare Disease Studies: Our Top Expert to Address WODC

DURHAM, N.C., APRIL 23, 2018 — Premier Research’s top rare disease and pediatrics expert will discuss clinical trial planning at the World Orphan Drug Congress in Oxon Hill, Maryland.

Angi Robinson, Executive Director, Strategic Development, Rare Disease & Pediatrics, will present Early Development Planning for Orphan Drugs: Tasks, Timelines, and Takeaways on Thursday, April 26, at 12:15 p.m. Topics will include:

  • Orphan drug designations: What they are, where they fit in, and how long they take to achieve
  • Natural history studies: purpose, design, and their role in producing meaningful data
  • Preparing for an IND/IMPD and related clinical studies

Aggressive pursuit of treatments for rare diseases continues 35 years after the Orphan Drug Act introduced wide-ranging industry incentives. Join us for an informative look at the current state of the industry and make sure to find us on the exhibit floor as one of the conference’s platinum’s sponsors. Finally, good luck to this year’s Pitch & Partner participants!

About Premier Research
Premier Research is a leading clinical development service provider that helps highly innovative biotech, specialty pharma, and medical device companies transform breakthrough ideas into reality. The company has a wealth of experience in the execution of global, regional and local clinical development programs with a special focus on addressing unmet needs in areas such as analgesia, dermatology, medical device, neuroscience, oncology, pediatrics, and rare disease. Premier Research operates in 84 countries and employs 1,250 professionals, including a strong international network of clinical monitors and project managers, regulatory, data management, statistical, scientific, and medical experts. They are focused on smart study design for advanced medicines that allow life-changing treatments.